No photo of Christopher J. Destache

View Scopus Profile

Christopher J. Destache, PharmD, FCCP

Professor

  • 2193 Citations
  • 25 h-Index
1985 …2019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 3 Similar Profiles
Nanoparticles Medicine & Life Sciences
Rilpivirine Medicine & Life Sciences
HIV-1 Medicine & Life Sciences
Pharmacokinetics Medicine & Life Sciences
Tenofovir Medicine & Life Sciences
Pharmaceutical Preparations Medicine & Life Sciences
HIV Medicine & Life Sciences
Therapeutics Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2008 2018

Long-acting antiretroviral nanoparticles for HIV prophylaxis

Destache, C. J.

National Institutes of Health

2/4/15 → 1/31/18

Project: Research project › Research Project

Nanoparticles
HIV
Rilpivirine
Tenofovir
Drug Combinations

Once Monthly Antiretroviral Nanoparticles for HIV-1 Treatment

Destache, C. J.

National Institutes of Health

6/15/11 → 5/31/13

Project: Research project › High Priority, Short Term Project Award

Nanoparticles
HIV-1
Therapeutics
Macaca
Macaca nemestrina

Pharmacology of Antiretroviral Nanoparticle Micelles

Destache, C. J.

National Institutes of Health

6/1/08 → 5/31/11

Project: Research project › Academic Research Enhancement Awards (AREA)

Micelles
Nanoparticles
HIV-1
Pharmacology
efavirenz

Research Output 1985 2019

Nanoencapsulation introduces long-acting phenomenon to tenofovir alafenamide and emtricitabine drug combination: A comparative pre-exposure prophylaxis efficacy study against HIV-1 vaginal transmission

Mandal, S., Kang, G., Prathipati, P. K., Zhou, Y., Fan, W., Li, Q. & Destache, C. J., Jan 28 2019, In : Journal of Controlled Release. 294, p. 216-225 10 p.

Research output: Contribution to journal › Article

Drug Combinations
HIV-1
Nanoparticles
GS-7340
Pre-Exposure Prophylaxis

Development and validation of LC–MS/MS method for quantification of bictegravir in human plasma and its application to an intracellular uptake study

Prathipati, P. K., Mandal, S. & Destache, C. J., Jan 1 2018, (Accepted/In press) In : Biomedical Chromatography. e4379.

Research output: Contribution to journal › Article

Plasma (human)
formic acid
Liquid chromatography
Mass spectrometers
Mass spectrometry
3 Citations

Discovery of a non-nucleoside RNA polymerase inhibitor for blocking Zika virus replication through in silico screening

Pattnaik, A., Palermo, N., Sahoo, B. R., Yuan, Z., Hu, D., Annamalai, A. S., Vu, H. L. X., Correas, I., Prathipati, P. K., Destache, C. J., Li, Q., Osorio, F. A., Pattnaik, A. K. & Xiang, S. H., Mar 1 2018, In : Antiviral Research. 151, p. 78-86 9 p.

Research output: Contribution to journal › Article

DNA-Directed RNA Polymerases
Virus Replication
Computer Simulation
RNA Replicase
Catalytic Domain

LC-MS/MS method for the simultaneous determination of tenofovir, emtricitabine, elvitegravir and rilpivirine in dried blood spots

Prathipati, P. K., Mandal, S. & Destache, C. J., Jan 1 2018, (Accepted/In press) In : Biomedical Chromatography.

Research output: Contribution to journal › Article

Rilpivirine
Tenofovir
formic acid
Blood
Assays
1 Citations

Long-acting parenteral combination antiretroviral loaded nano-drug delivery system to treat chronic HIV-1 infection: A humanized mouse model study

Mandal, S., Kang, G., Prathipati, P. K., Fan, W., Li, Q. & Destache, C. J., Aug 1 2018, In : Antiviral Research. 156, p. 85-91 7 p.

Research output: Contribution to journal › Article

Virus Diseases
Drug Delivery Systems
Viral Load
HIV-1
Nanoparticles